Optimal duration of pre‐liver transplantation anti‐hepatitis C virus treatment with direct‐acting agent sofosbuvir

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|6|1776-1776

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.6, 2015-06, pp. : 1776-1776

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Late hepatitis B reactivation following direct‐acting antiviral–based treatment of recurrent hepatitis C in an anti‐HBc–positive liver transplant recipient

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 791-793

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 129-134

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 3, 2015-03 ,pp. : 408-409

John Wiley & Sons Inc

Access to resources Recommend Favorite

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals

By  

Oncology, Vol. 91, Iss. 6, 2016-10 ,pp. : 341-347

Karger

Access to resources Recommend Favorite

Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 7-13

John Wiley & Sons Inc

Access to resources Recommend Favorite